Viking Therapeutics, Inc. (NASDAQ:VKTX - Free Report) - Stock analysts at Leerink Partnrs lowered their FY2029 earnings estimates for Viking Therapeutics in a research report issued on Thursday, October 23rd. Leerink Partnrs analyst T. Smith now forecasts that the biotechnology company will post earnings of $5.13 per share for the year, down from their prior forecast of $5.16. The consensus estimate for Viking Therapeutics' current full-year earnings is ($1.56) per share.
Viking Therapeutics (NASDAQ:VKTX - Get Free Report) last released its quarterly earnings data on Wednesday, October 22nd. The biotechnology company reported ($0.81) EPS for the quarter, missing analysts' consensus estimates of ($0.67) by ($0.14). During the same period in the previous year, the business earned ($0.22) EPS. The business's quarterly revenue was up .0% on a year-over-year basis.
A number of other brokerages have also recently weighed in on VKTX. BTIG Research reiterated a "buy" rating and set a $125.00 price target on shares of Viking Therapeutics in a research report on Monday, September 22nd. Weiss Ratings reissued a "sell (d-)" rating on shares of Viking Therapeutics in a research note on Wednesday, October 8th. HC Wainwright reissued a "buy" rating and set a $102.00 target price on shares of Viking Therapeutics in a research note on Monday, September 29th. Zacks Research lowered Viking Therapeutics from a "hold" rating to a "strong sell" rating in a report on Tuesday. Finally, Morgan Stanley increased their price objective on Viking Therapeutics from $98.00 to $102.00 and gave the stock an "overweight" rating in a report on Thursday. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, two have issued a Hold rating and two have issued a Sell rating to the company's stock. According to data from MarketBeat.com, Viking Therapeutics currently has an average rating of "Moderate Buy" and a consensus target price of $86.50.
Read Our Latest Research Report on VKTX
Viking Therapeutics Stock Up 8.0%
Shares of NASDAQ:VKTX opened at $33.92 on Friday. The firm has a 50-day simple moving average of $28.68 and a 200 day simple moving average of $28.63. The company has a market cap of $3.81 billion, a PE ratio of -16.00 and a beta of 0.64. Viking Therapeutics has a fifty-two week low of $18.92 and a fifty-two week high of $81.73.
Institutional Investors Weigh In On Viking Therapeutics
A number of institutional investors have recently added to or reduced their stakes in the company. Harbour Investments Inc. lifted its position in Viking Therapeutics by 2.2% in the second quarter. Harbour Investments Inc. now owns 14,961 shares of the biotechnology company's stock worth $396,000 after purchasing an additional 326 shares during the period. Allworth Financial LP boosted its stake in Viking Therapeutics by 58.4% during the second quarter. Allworth Financial LP now owns 955 shares of the biotechnology company's stock valued at $25,000 after buying an additional 352 shares in the last quarter. Montag A & Associates Inc. boosted its stake in Viking Therapeutics by 6.1% during the second quarter. Montag A & Associates Inc. now owns 6,220 shares of the biotechnology company's stock valued at $165,000 after buying an additional 358 shares in the last quarter. Lewis Asset Management LLC boosted its stake in Viking Therapeutics by 0.9% during the second quarter. Lewis Asset Management LLC now owns 44,060 shares of the biotechnology company's stock valued at $1,168,000 after buying an additional 385 shares in the last quarter. Finally, HighMark Wealth Management LLC boosted its stake in Viking Therapeutics by 9.4% during the first quarter. HighMark Wealth Management LLC now owns 4,660 shares of the biotechnology company's stock valued at $113,000 after buying an additional 400 shares in the last quarter. 76.03% of the stock is currently owned by institutional investors and hedge funds.
Viking Therapeutics Company Profile
(
Get Free Report)
Viking Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Viking Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Viking Therapeutics wasn't on the list.
While Viking Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
We are about to experience the greatest A.I. boom in stock market history...
Thanks to a pivotal economic catalyst, specific tech stocks will skyrocket just like they did during the "dot com" boom in the 1990s.
That’s why, we’ve hand-selected 7 tiny tech disruptor stocks positioned to surge.
- The first pick is a tiny under-the-radar A.I. stock that's trading for just $3.00. This company already has 98 registered patents for cutting-edge voice and sound recognition technology... And has lined up major partnerships with some of the biggest names in the auto, tech, and music industry... plus many more.
- The second pick presents an affordable avenue to bolster EVs and AI development…. Analysts are calling this stock a “buy” right now and predict a high price target of $19.20, substantially more than its current $6 trading price.
- Our final and favorite pick is generating a brand-new kind of AI. It's believed this tech will be bigger than the current well-known leader in this industry… Analysts predict this innovative tech is gearing up to create a tidal wave of new wealth, fueling a $15.7 TRILLION market boom.
Right now, we’re staring down the barrel of a true once-in-a-lifetime moment. As an investment opportunity, this kind of breakthrough doesn't come along every day.
And the window to get in on the ground-floor — maximizing profit potential from this expected market surge — is closing quickly...
Simply enter your email below to get the names and tickers of the 7 small stocks with potential to make investors very, very happy.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
